Previous 10 | Next 10 |
Interpace Biosciences (IDXG): Q1 GAAP EPS of -$1.02 beats by $0.41.Revenue of $9.83M (+8.5% Y/Y) beats by $0.83M.Press Release For further details see: Interpace Biosciences EPS beats by $0.41, beats on revenue
PARSIPPANY, NJ, May 11, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended March 31, 2021 and provided a business and financial update. “We ar...
Parsippany, NJ, May 03, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that eviCore Healthcare (“eviCore”), a wholly owned subsidiary of Cigna, has updated their laboratory managemen...
Parsippany, NJ, April 22, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today issued the following statement. Interpace continues to make progress executing its growth strategy and the Company recently inc...
Interpace Biosciences (IDXG) raises FY 2021 revenue to be in the range of $42M-44M as compared to the prior guidance of $38M-40M, representing an ~30% to 36% improvement Y/Y vs. consensus of $39.6M."With the revenue growth and restructuring progressing as planned, expectations ...
Parsippany, NJ, April 19, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced an update to its full year 2021 revenue guidance originally provided on March 31, 2021. "We saw increased and sustain...
Parsippany, NJ, April 12, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today new capability in advancing RNA biomarker analysis for gene and cell-based ther...
Parsippany, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that Novitas, its Medicare Administrative Contractor, has agreed to recognize the new Proprietary Laboratory Analysis ...
Interpace Biosciences (IDXG): Q4 GAAP EPS of -$2.01 misses by $0.69.Revenue of $9.65M (+129.2% Y/Y) beats by $0.15M.Press Release For further details see: Interpace Biosciences EPS misses by $0.69, beats on revenue
2020 Full Year Net Revenue of $32.4 Million Up 34% vs Prior Year; Fourth Quarter Net Revenue of $9.6M Million Up 129% vs Prior Year; Provides Full Year 2021 Range of Revenues On Target to Achieve EBITDA Breakeven by 2021 Year End PARSIPPANY, NJ, March 31, 2021 (G...
News, Short Squeeze, Breakout and More Instantly...
Interpace Biosciences Inc. Company Name:
IDXG Stock Symbol:
NASDAQ Market:
Interpace Biosciences Inc. Website:
PARSIPPANY, NJ, June 04, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics ® , a subsidiary of Interpace Biosciences ® (OTCQX: IDXG), is proud to announce that new data demonstrating the application of advanced sequencing technologies in pancreatic cancer was published as an e-ab...
PARSIPPANY, NJ, May 09, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2024 and provided a business and financial update. First quarter Net ...
GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...